ClinicalTrials.gg
TerminatedNCT04985604Updated Oct 2, 2025Results posted

Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors

A Phase 2 interventional study of Tovorafenib in Melanoma, Solid Tumor and CRAF Gene Amplification, sponsored by Day One Biopharmaceuticals, Inc.. Terminated at 20 sites in 7 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2025-10-02.

Sponsored by Day One Biopharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

Why this study was terminated
Sponsor decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
23
Allocation
Non-randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,049 studies in Melanoma with a site in United States — 243 open to participants now, 440 under way, 32 of them phase 3. Melanoma · United States.

Enrollment
1,121st of 1,749
23 · median 37
Started
2021
with 105 others
Phase 2
612 of 2,049
46 open now
Registered
1,667th of 2,049
by date

Among the 2,049 studies in Melanoma with a site in United States, this one is the 1,121st largest by enrollment of the 1,749 interventional ones that give a count, is one of 106 that started in 2021, is one of 612 in phase 2, and was the 1,667th registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

243 of the 2,049 studies in Melanoma with a site in United States are open now. Recruiting first, the newest first:

238 more — sign in →

All 243 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,049 studies in Melanoma with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2, multi-center, open-label to evaluate the efficacy and safety of tovorafenib (DAY101) in participants ≥12 years of age with recurrent or progressive melanoma or solid tumors with BRAF fusion or CRAF/RAF1 fusions or amplification.

03

Conditions studied

  • Melanoma
  • Solid Tumor
  • CRAF Gene Amplification
  • RAF1 Gene Amplification
  • BRAF Gene Fusion
  • BRAF Fusion
  • CRAF Gene Fusion
  • CRAF Fusion
  • RAF1 Gene Fusion
  • RAF1 Fusion
  • Thyroid Cancer, Papillary
  • Spitzoid Melanoma
  • Pilocytic Astrocytoma
  • Pilocytic Astrocytoma, Adult
  • Non Small Cell Lung Cancer
  • Non-Small Cell Adenocarcinoma
  • Colorectal Cancer
  • Pancreatic Acinar Carcinoma
  • Spitzoid Malignant Melanoma
  • Bladder Cancer
  • Bladder Urothelial Carcinoma
  • MAP Kinase Family Gene Mutation
  • RAF Mutation

Keywords

  • BRAF fusion
  • CRAF/RAF1 fusion
  • CRAF/RAF1 amplification
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed by participants ≥ 12 years of age either a Consent or an Assent Form will be provided to the patient based on their capacity, local regulations, and guidelines.
  • Participants must have a confirmed diagnosis of melanoma or other solid tumor and a BRAF fusion, CRAF/RAF1 fusion, or CRAF/RAF1 amplifications obtained through a tumor or liquid as assessed by genomic sequencing, polymerase chain reaction (PCR), fluorescence in situ hybridization (FISH), or another clinically accepted molecular diagnostic method recognized by local laboratory or regulatory agency.
  • Participants must have radiographically-recurrent or radiographically-progressive disease that is measurable using the appropriate tumor response criteria (e.g. version 1.1 or RANO).
  • Archival tumor tissue (preferably less than 3 years old) or fresh tumor tissue for correlative studies is required
  • If are present, they must have been previously treated and be stable as assessed by radiographic imaging

Exclusion criteria

Exclusion Criteria:

  • Prior therapy of any RAS-, RAF-, MEK-, or ERK-directed inhibitor therapy
  • Known presence of concurrent activating mutation
  • Participants with current evidence or a history of central serous retinopathy (CSR), retinal vein occlusion (RVO)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Melanoma Cohort

    Tovorafenib monotherapy

    Drug: Tovorafenib

  • Experimental
    Tissue Agnostic Cohort

    Tovorafenib monotherapy

    Drug: Tovorafenib

Interventions

  • Tovorafenib tablet for oral use.

    Also known as: DAY101

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR) by the Investigator

    ORR was defined as the percentage of participants with the best overall confirmed response of complete response (CR) or partial response (PR) according to the appropriate response assessment criteria including Response Evaluation Criteria in Solid Tumors (RECIST 1.1) or Response Assessment in Neuro-Oncology (RANO) for the disease setting as assessed by the Investigator. CR or PR was confirmed at a subsequent scan (\>=4 weeks) if the criteria for each are met . The exact 95% confidence intervals (CIs) were calculated using Clopper-Pearson method.

    Time frame: Up to 23 months

Secondary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    An adverse event (AE) is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An serious adverse event (SAE) is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgment. An AE is considered to be treatment-emergent if it has a start date/time on or after the first administration of study drug until 30 days after the last dose of study drug and before the start of subsequent therapy, whichever comes earlier. The distribution of AEs was analyzed by the type, frequency and severity for TEAEs.

    Time frame: Up to 23 months

  2. Number of Participants With Worst Case Hematology Results by Maximum Grade Increase Post-baseline Relative to Baseline

    Blood samples were collected for the analysis of following hematology parameters: anemia, neutrophil count decreased and white blood cell decreased. Grade 1 (G1): mild; Grade 2 (G2): moderate; Grade 3 (G3): severe; Grade 4 (G4) life-threatening or disabling. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Any worst-case post baseline increase to G2, G3, and G4 are presented. The laboratory parameters were graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.

    Time frame: Baseline and up to 23 months

  3. Number of Participants With Worst Case Chemistry Results by Maximum Grade Increase Post-baseline Relative to Baseline

    Blood samples were collected for the analysis of following chemistry parameters: creatine phosphokinase (CPK) increased, hypokalemia, hypoalbuminemia, hypercalcemia, hypocalcemia and hyponatremia. Grade 1 (G1): mild; Grade 2 (G2): moderate; Grade 3 (G3): severe; Grade 4 (G4) life-threatening or disabling. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Any worst-case post baseline increase to G2, G3, and G4 are presented. The laboratory parameters were graded according to CTCAE version 5.

    Time frame: Baseline and up to 23 months

  4. Duration of Response (DOR) in Participants With Best Overall Response

    Duration of response was defined as the interval from the date of the first documentation of tumor response (CR or PR) that was subsequently confirmed by investigator assessment to the date of first occurrence of radiographic disease progression based on RECIST 1.1 or RANO criteria or death due to any cause, whichever occurs earlier. DOR was estimated using Kaplan-Meier method.

    Time frame: Up to 23 months

  5. Duration of Progression Free Survival

    Progression free survival was defined as the interval from the date of the first dose to the first occurrence of radiographic disease progression based on RECIST 1.1 or RANO criteria or death due to any cause, whichever occurs earlier. Progression free survival was estimated using Kaplan-Meier method.

    Time frame: Up to 23 months

  6. Duration of Overall Survival

    Overall survival is defined as the interval from the date of the first dose until the recorded date of death due to any cause. Overall survival was estimated using Kaplan-Meier method.

    Time frame: Up to 23 months

  7. Time to Response

    Time to Response was defined in participants with best overall response of complete response or partial response as determined by Investigator. It is the interval from the date of the first dose to date of first documentation of tumor response that was subsequently confirmed by investigator assessment.

    Time frame: Up to 23 months

07

Results

Posted Oct 2, 2025

Participant flow

This study was conducted at 11 centers that enrolled participants in 6 countries.

Participant flow — Overall Study
MilestoneMelanoma CohortTissue Agnostic Cohort
Started815
Completed48
Not completed47
Withdrew: Death46
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryOverall Response Rate (ORR) by the Investigator

ORR was defined as the percentage of participants with the best overall confirmed response of complete response (CR) or partial response (PR) according to the appropriate response assessment criteria including Response Evaluation Criteria in Solid Tumors (RECIST 1.1) or Response Assessment in Neuro-Oncology (RANO) for the disease setting as assessed by the Investigator. CR or PR was confirmed at a subsequent scan (\>=4 weeks) if the criteria for each are met . The exact 95% confidence intervals (CIs) were calculated using Clopper-Pearson method.

Time frame:
Up to 23 months
Reported as:
Number · Percentage of participants
Overall Response Rate (ORR) by the Investigator
Percentage of participantsMelanoma CohortTissue Agnostic Cohort
Overall Response Rate (ORR) by the Investigator50.0 (15.7 to 84.3)40.0 (16.3 to 67.7)
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs)

An adverse event (AE) is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An serious adverse event (SAE) is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgment. An AE is considered to be treatment-emergent if it has a start date/time on or after the first administration of study drug until 30 days after the last dose of study drug and before the start of subsequent therapy, whichever comes earlier. The distribution of AEs was analyzed by the type, frequency and severity for TEAEs.

Time frame:
Up to 23 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsMelanoma CohortTissue Agnostic Cohort
Any TEAE815
TEAEs Related to Study Drug813
Any serious TEAE28
Serious TEAEs Related to Study Drug01
TEAEs with Severity Grade 3 or Higher58
TEAEs Related to Study Drug with Severity Grade 3 or Higher23
TEAEs Leading to Death00
TEAEs Related to Study Drug Leading to Death00
TEAEs Leading to Study Drug Discontinuation10
TEAEs Related to Study Drug Leading to Study Drug Discontinuation10
SecondaryNumber of Participants With Worst Case Hematology Results by Maximum Grade Increase Post-baseline Relative to Baseline

Blood samples were collected for the analysis of following hematology parameters: anemia, neutrophil count decreased and white blood cell decreased. Grade 1 (G1): mild; Grade 2 (G2): moderate; Grade 3 (G3): severe; Grade 4 (G4) life-threatening or disabling. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Any worst-case post baseline increase to G2, G3, and G4 are presented. The laboratory parameters were graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.

Time frame:
Baseline and up to 23 months
Reported as:
Count of participants · Participants
Number of Participants With Worst Case Hematology Results by Maximum Grade Increase Post-baseline Relative to Baseline
ParticipantsMelanoma CohortTissue Agnostic Cohort
Anemia, Increased to Grade 235
Anemia, Increased to Grade 322
Anemia, Increased to Grade 400
Neutrophil count decreased, Increased to Grade 202
Neutrophil count decreased, Increased to Grade 301
Neutrophil count decreased, Increased to Grade 400
White blood cell decreased, Increased to Grade 202
White blood cell decreased, Increased to Grade 300
White blood cell decreased, Increased to Grade 400
SecondaryNumber of Participants With Worst Case Chemistry Results by Maximum Grade Increase Post-baseline Relative to Baseline

Blood samples were collected for the analysis of following chemistry parameters: creatine phosphokinase (CPK) increased, hypokalemia, hypoalbuminemia, hypercalcemia, hypocalcemia and hyponatremia. Grade 1 (G1): mild; Grade 2 (G2): moderate; Grade 3 (G3): severe; Grade 4 (G4) life-threatening or disabling. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Any worst-case post baseline increase to G2, G3, and G4 are presented. The laboratory parameters were graded according to CTCAE version 5.

Time frame:
Baseline and up to 23 months
Reported as:
Count of participants · Participants
Number of Participants With Worst Case Chemistry Results by Maximum Grade Increase Post-baseline Relative to Baseline
ParticipantsMelanoma CohortTissue Agnostic Cohort
CPK increased, Increased to Grade 224
CPK increased, Increased to Grade 301
CPK increased, Increased to Grade 410
Hypoalbuminemia, Increased to Grade 212
Hypoalbuminemia, Increased to Grade 300
Hypoalbuminemia, Increased to Grade 400
Hypokalemia, Increased to Grade 215
Hypokalemia, Increased to Grade 301
Hypokalemia, Increased to Grade 400
Hyponatremia, Increased to Grade 211
Hyponatremia, Increased to Grade 300
Hyponatremia, Increased to Grade 400
Hypercalcemia, Increased to Grade 200
Hypercalcemia, Increased to Grade 301
Hypercalcemia, Increased to Grade 400
Hypocalcemia, Increased to Grade 201
Hypocalcemia, Increased to Grade 300
Hypocalcemia, Increased to Grade 400
SecondaryDuration of Response (DOR) in Participants With Best Overall Response

Duration of response was defined as the interval from the date of the first documentation of tumor response (CR or PR) that was subsequently confirmed by investigator assessment to the date of first occurrence of radiographic disease progression based on RECIST 1.1 or RANO criteria or death due to any cause, whichever occurs earlier. DOR was estimated using Kaplan-Meier method.

Time frame:
Up to 23 months
Reported as:
Median · Months
Duration of Response (DOR) in Participants With Best Overall Response
MonthsMelanoma CohortTissue Agnostic Cohort
Duration of Response (DOR) in Participants With Best Overall Response5.6 (3.0 to NA)9.2 (3.5 to NA)
SecondaryDuration of Progression Free Survival

Progression free survival was defined as the interval from the date of the first dose to the first occurrence of radiographic disease progression based on RECIST 1.1 or RANO criteria or death due to any cause, whichever occurs earlier. Progression free survival was estimated using Kaplan-Meier method.

Time frame:
Up to 23 months
Reported as:
Median · Months
Duration of Progression Free Survival
MonthsMelanoma CohortTissue Agnostic Cohort
Duration of Progression Free Survival5.5 (1.8 to 12.5)5.5 (1.7 to NA)
SecondaryDuration of Overall Survival

Overall survival is defined as the interval from the date of the first dose until the recorded date of death due to any cause. Overall survival was estimated using Kaplan-Meier method.

Time frame:
Up to 23 months
Reported as:
Median · Months
Duration of Overall Survival
MonthsMelanoma CohortTissue Agnostic Cohort
Duration of Overall Survival18.9 (3.4 to NA)NA (5.5 to NA)
SecondaryTime to Response

Time to Response was defined in participants with best overall response of complete response or partial response as determined by Investigator. It is the interval from the date of the first dose to date of first documentation of tumor response that was subsequently confirmed by investigator assessment.

Time frame:
Up to 23 months
Reported as:
Median · Months
Time to Response
MonthsMelanoma CohortTissue Agnostic Cohort
Time to Response1.76 (1.66 to 6.44)1.82 (1.77 to 1.87)

Adverse events

Collected over Up to 23 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Melanoma Cohort4/8 (50%)2/8 (25%)8/8 (100%)
Tissue Agnostic Cohort6/15 (40%)8/15 (53.3%)15/15 (100%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventMelanoma CohortTissue Agnostic Cohort
EpistaxisRespiratory, thoracic and mediastinal disorders1/80/15
Tumour associated feverNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/80/15
AnaemiaBlood and lymphatic system disorders0/81/15
EncephalopathyNervous system disorders0/81/15
Haemorrhage intracranialNervous system disorders0/81/15
HemiparesisNervous system disorders0/81/15
HypercalcaemiaMetabolism and nutrition disorders0/81/15
Metastases to lungNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/81/15
Musculoskeletal chest painMusculoskeletal and connective tissue disorders0/81/15
NauseaGastrointestinal disorders0/81/15
Most frequent other events
Showing 10 of 113
Most frequent other events
EventMelanoma CohortTissue Agnostic Cohort
AnaemiaBlood and lymphatic system disorders5/87/15
FatigueGeneral disorders4/80/15
MyalgiaMusculoskeletal and connective tissue disorders1/86/15
ConstipationGastrointestinal disorders3/83/15
Face oedemaGeneral disorders3/82/15
PruritusSkin and subcutaneous tissue disorders3/84/15
RashSkin and subcutaneous tissue disorders3/83/15
Blood creatine phosphokinase increasedInvestigations1/85/15
VomitingGastrointestinal disorders1/84/15
AstheniaGeneral disorders0/84/15

Baseline characteristics

Safety Analysis Set comprised of all participants enrolled in the study who received at least one dose of study treatment.

Age, Continuous
Age, Continuous(Years)Melanoma CohortTissue Agnostic CohortTotal
Median58.0 (26 to 71)45.0 (21 to 71)53.0 (21 to 71)
Sex: Female, Male
Sex: Female, Male(Participants)Melanoma CohortTissue Agnostic CohortTotal
Female4711
Male4812
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Melanoma CohortTissue Agnostic CohortTotal
Hispanic or Latino112
Not Hispanic or Latino71421
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Melanoma CohortTissue Agnostic CohortTotal
American Indian or Alaska Native000
Asian516
Native Hawaiian or Other Pacific Islander000
Black or African American000
White31013
More than one race022
Unknown or Not Reported022
08

Study locations

20 sites
  • The Angeles Clinic
    Los Angeles, California 90025, United States
  • Hoag Health
    Newport Beach, California 92663, United States
  • University of Colorado Hospital
    Aurora, Colorado 80045, United States
  • Cancer Specialists of North Florida
    Jacksonville, Florida 32256, United States
  • Community North Cancer Center
    Indianapolis, Indiana 46250, United States
  • OHSU Knight Cancer Institute
    Portland, Oregon 97239, United States
  • UPMC Hillman Cancer Center
    Pittsburgh, Pennsylvania 15213, United States
  • Vanderbilt-Ingram Cancer Center
    Nashville, Tennessee 37232, United States
  • Monash Medical Centre
    Clayton, Victoria, Australia
  • Antwerp University Hospital
    Edegem, Belgium
  • Princess Margaret Cancer Centre
    Toronto, Ontario, Canada
  • The Hospital for Sick Children
    Toronto, Ontario, Canada
  • Hopital de La Timone - APHM
    Marseille, Bouches-du-Rhône, France
  • Dong-A University Hospital
    Busan, South Korea
  • Asan Medical Center
    Seoul, South Korea
  • Samsung Medical Center
    Seoul, South Korea
  • Severance Hospital, Yonsei University Health System
    Seoul, South Korea
  • Hospital Clinic Barcelona
    Barcelona, Spain
  • Hospital Universitari Vall d'Hebron
    Barcelona, Spain
  • Hospital Universitario Ramón y Cajal
    Madrid, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2021 to primary completion in Jul 2024, 35 months.

Results were first posted in Oct 2025, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2021
First posted
Aug 2, 2021
StartActual
Jul 15, 2021
Primary completionActual
Jul 8, 2024
CompletionActual
Jul 8, 2024
Results first posted
Oct 2, 2025
Last update
Oct 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04985604
Lead sponsor
Day One Biopharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Aug 2, 2021
Start date
Jul 15, 2021
Primary completion
Jul 8, 2024
Completion
Jul 8, 2024
Results posted
Oct 2, 2025
Last update
Oct 2, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tovorafenib

Start the discussion